The Occurence of Inflammation and Oxidative Stress in Lung Diseases

This study has been completed.
Sponsor:
Collaborator:
ZonMw: The Netherlands Organisation for Health Research and Development
Information provided by:
Maastricht University Medical Center
ClinicalTrials.gov Identifier:
NCT00512967
First received: July 19, 2007
Last updated: February 25, 2008
Last verified: February 2008
  Purpose

Reactive oxygen species (ROS) are suggested to play a pivotal role in ILD. Little is known, however, about the endogenous antioxidant levels in ILD that can offer protection against ROS. It is expected that the high amount of ROS present in ILD will reduce the antioxidant levels. Therefore, antioxidant therapy to strengthen this reduced antioxidant defense might be efficacious in ILD treatment. Since ROS are capable of initiating and mediating inflammation, antioxidant therapy might also mitigate elevated inflammation. A candidate for antioxidant therapy is the flavonoid quercetin that is known for its anti-oxidative and anti-inflammatory capacities.

The aim of the present study is to determine the antioxidant and inflammatory status in ILD, i.e. sarcoidosis and idiopathic pulmonary fibrosis (IPF). Furthermore, to evaluate the possible anti-inflammatory effects of antioxidants, the effect of quercetin will be examined on the ex vivo LPS-induced cytokine production in ILD


Condition
Interstitial Lung Diseases
Sarcoidosis
Idiopathic Pulmonary Fibrosis
COPD

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Cross-Sectional
Official Title: The Inflammatory and Antioxidant Status in Pulmonary Sarcoidosis, Idiopathic Pulmonary Fibrosis and COPD: a Potential Role for Antioxidants

Resource links provided by NLM:


Further study details as provided by Maastricht University Medical Center:

Biospecimen Retention:   Samples With DNA

blood samples were collected


Enrollment: 76
Study Start Date: September 2005
Study Completion Date: June 2006
Groups/Cohorts
sarcoidosis
21 onset patients, non-treated
IPF
15 IPF patients, partially treated
COPD
15 COPD patients within 24 hours after their last exacerbation
controls
25 healthy controls, matched for age and gender

  Show Detailed Description

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

lung patients visiting the out-patient clinic of the Academic Hospital Maastricht

Criteria

Inclusion Criteria:

  • clinical diagnosis of pulmonary sarcoidosis, IPF or COPD
  • no treatment for sarcoidosis
  • last exacerbation not more than 24 hours ago for COPD
  • healthy controls
  • no smoking for sarcoidosis and IPF

Exclusion Criteria:

  • pregnancy
  • use of vitamins or food supplements
  • clinical diagnosis (and treatment) of other diseases
  • symptoms of sarcoidosis in other organs besides the lung
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00512967

Locations
Netherlands
Maastricht University
Maastricht, Netherlands, 6224 LH
Sponsors and Collaborators
Maastricht University
ZonMw: The Netherlands Organisation for Health Research and Development
Investigators
Study Chair: Aalt Bast, PhD Maastricht University
Principal Investigator: Agnes W Boots, PhD Maastricht University
Study Director: Guido R Haenen, PhD Maastricht University
  More Information

No publications provided

Responsible Party: Dr. A.W. Boots, Maastricht University
ClinicalTrials.gov Identifier: NCT00512967     History of Changes
Other Study ID Numbers: MEC 03-112
Study First Received: July 19, 2007
Last Updated: February 25, 2008
Health Authority: Netherlands: Medical Ethics Review Committee (METC)

Keywords provided by Maastricht University Medical Center:
oxidative stress
antioxidants
inflammation
quercetin

Additional relevant MeSH terms:
Fibrosis
Inflammation
Lung Diseases
Pulmonary Disease, Chronic Obstructive
Pulmonary Fibrosis
Sarcoidosis
Sarcoidosis, Pulmonary
Lung Diseases, Interstitial
Idiopathic Pulmonary Fibrosis
Pathologic Processes
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lymphoproliferative Disorders
Lymphatic Diseases
Idiopathic Interstitial Pneumonias
Antioxidants
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Protective Agents
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on April 17, 2014